Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927238 · ClinicalTrials.gov registry record · Phase 3
XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)
A Phase 3 study, sponsored by NuVasive.
- Completed
- Registry status
- Phase 3
- Development phase
- 246
- Enrollment target
NCT00927238 is a Phase 3 study that has completed, run by NuVasive. The registered enrollment target is 246 participants.
The verdict
NCT00927238, a Phase 3 study, has completed, sponsored by NuVasive.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of XL TDR in patients with single-level degenerative disc disease compared to other devices approved by the FDA for the same or similar indications.
Interventions
- DEVICE XL TDR
- OTHER Lumbar fusion surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927238
The ClinicalTrials.gov registry entry for NCT00927238 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuVasive, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XL TDR is the first listed.
NCT00927238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00927238 about?
NCT00927238 is a clinical study titled "XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)". The purpose of this study is to evaluate the safety and effectiveness of XL TDR in patients with single-level degenerative disc disease compared to other devices approved by the FDA for the same or similar indications.
What is the current status of trial NCT00927238?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 246 participants. The study started on 2009-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00927238?
The interventions under investigation include: XL TDR (DEVICE), Lumbar fusion surgery (OTHER).
Who is sponsoring clinical trial NCT00927238?
This trial is sponsored by NuVasive, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.